GlassScriptPhysician profile
Bethany T Gibson
NPI 1043278013
$767.80
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $233 · 2021: $145 · 2022: $83.33.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $353.77 | 2019-2022 | |
| Pfizer INC. | $122.68 | 2019-2020 | |
| Optinose US, INC. | $85.64 | 2021-2022 | |
| Genzyme Corporation | $77.62 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $48.79 | 2019-2020 | |
| Alk-Abello, INC | $48.41 | 2019 | |
| Csl Behring | $16.29 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.60 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.